Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Post by nodaytraderon Jul 05, 2024 11:08am

154 Views

Post# 36119685

Today’s Depth Display on CSE

While trade price is hovering around 12 cents, if you remove the Quebec kids (Desjardins and National Bank), from the Depth Display, the lowest offer on the Depth Didplay is17 cents. Of the offers between 13 and 17 cents, National has only one, 1000 shares at 14 cents - everything else is Desjardins.
I have two questions.
1. Does this mean that Desjardins, virtually single-handedly, is suppressing the share price?
2. Is this really a market?

<< Previous

Bullboard Posts

Rogers buys out Bell, becomes majority owner of MLSE and Maple Leafs